Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Unlocking the potential of saliva-based test to detect HPV-driven oropharyngeal cancer.

Date

24 Nov 2018

Session

Poster display - Cocktail

Presenters

Kai Dun Tang

Citation

Annals of Oncology (2018) 29 (suppl_9): ix94-ix104. 10.1093/annonc/mdy438

Authors

K.D. Tang, C. Punyadeera

Author affiliations

  • The School Of Biomedical Sciences/ihbi, Queensland University of Technology, 4059 - Brisbane/AU
More

Resources

Abstract 1244

Background

The incidence of human papillomavirus (HPV)-driven oropharyngeal cancer (OPC) is increasing in the developed countries including Australia. Accumulating evidence supports the notion that an accurate HPV testing is crucial for clinical decision making and treatment planning in these patients.

Methods

HPV positivity in patients who have been diagnosed with OPC tumours (n = 105) was examined using p16INK4A immunohistochemistry (IHC) analysis. HPV-16 genotyping and physical status in salivary oral rinse and tumour samples were analyzed using qPCR method.

Results

The inter-rater agreement between OPC tumour p16INK4A expression and oral HPV-16 infection was considered as fair (k = 0.387). Salivary HPV-16 DNA (E2 and/or E6/7) was detected in 73 out of 95 p16INK4A-positive OPC patients. Importantly, HPV-16 genotyping and the ratio of HPV16 E2 DNA to HPV16 E6/7 DNA were concordant between the salivary oral rinse and tumour samples. Consistent with previous studies, for the majority of OPC patients, a mixed HPV-16 form (episomal and integrated) was detected in both sample methods, suggesting that salivary HPV-16 could be used as a potential biomarker for OPC.

Conclusions

HPV-16 detection in saliva is an attractive non-invasive method that can easily be implemented either as a dentist-chair side test or as a laboratory developed test to detect HPV-driven OPC.

Editorial acknowledgement

Clinical trial identification

Legal entity responsible for the study

Saliva Translational Research Group.

Funding

Atlantic Philanthropies, the Queensland Government.

Disclosure

All authors have declared no conflicts of interest.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings